Furthermore, recent evidence suggests that, in addition to conventional blood pressure management with renin-angiotensin system inhibitors and calcium channel blockers, SGLT2 inhibitors may be beneficial as prevention for the recurrence of atrial fibrillation after catheter ablation for CKD [30]. This evidence concerns the gene SLC5A2 and chronic kidney disease.